BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBTelix expands US radiopharma footprint with $250M RLS buy. Radiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of... Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
Media and podcasts - BioWorld
WEBBioWorld Insider Podcast. One-on-one with medical innovators. Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating ...
BioWorld: The Daily Biopharmaceutical News Source
WEBThe FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the first to act via a novel mechanism for the serious psychiatric disorder in over 50 years, finally expanding the treatment options beyond dopamine-targeted therapies.
Lerna Biopharma presents first-in-class GalNAc-siRNA ... - BioWorld
WEBNov 23, 2023 · Researchers from Lerna Biopharma Pte. Ltd. (formerly Cargene Therapeutics Pte. Ltd.) recently presented the discovery and preclinical evaluation of a first-in-class GalNAc-siRNA therapeutic, CG-LR1, being developed for …
Genor wins $440M+ cancer drug deal with Third Rock/Two River …
WEBAug 7, 2024 · Genor wins $440M+ cancer drug deal with Third Rock/Two River firm. Aug. 7, 2024. By Marian (YoonJee) Chu. China’s Genor Biopharma Co. Ltd. agreed to out-license GB-261, its bispecific antibody candidate primarily targeting B-cell lymphomas, to TRC 2004 Inc., a U.S.-based newco co-founded by Third Rock …
US researchers identify new GTPase KRAS (G12D mutant) inhibitors
WEBMarch 7, 2024. Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. have jointly disclosed new GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer. BioWorld Science Cancer Patents. Big pharma eyes China ‘at forefront of GLP-1 revolution’. Two leading glucagon-like peptide-1 ...
Microbiotica entering clinic with live bacterial therapeutics
WEBAug 30, 2024 · Microbiotica Ltd. is poised to advance two of its microbiome-derived products into the clinic after securing regulatory approval and fresh finance. The first live bacterial therapeutic, MB-097, will be tested in combination with Keytruda (pembrolizumab) in patients with advanced melanoma who have not responded to treatment with immune checkpoint inhibitors.
MK-5661, a potent Nav1.8 inhibitor with promising safety and
WEBApr 4, 2024 · MK-5661, a potent Nav1.8 inhibitor with promising safety and low oral dose predictions. Discovery of novel Nav1.8 inhibitors capable of achieving high levels of target modulation at low oral doses for the potential treatment of pain was reported by Merck & Co. Inc. Strategics tend to invest in med-tech companies they are looking to acquire or ...
Mironid divulges new phosphodiesterase PDE4 activators
WEBMar 11, 2024 · Mironid Ltd. has synthesized phosphodiesterase PDE4 activators reported to be useful for the treatment cancer, hyperparathyroidism, autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease. Nine years on from securing $3.84 million for a phase I clinical trial to test …
Nextgen Bioscience patents compounds acting as HIF-1α or …
WEBMar 4, 2024 · Nextgen Bioscience Co. Ltd. describes new compounds acting as hypoxia inducible factor-1α (HIF-1α) or vascular endothelial growth factor receptor (VEGFR) inhibitors and reported to be useful for the treatment of stroke, cancer, obesity, asthma, glaucoma, inflammatory bowel disease, rheumatoid arthritis …